相似文献
1
Warding Off Recurrent Yeast and Bacterial Vaginal Infections: Lactoferrin and Lactobacilli.
Microorganisms. 2020 Jan 17;8(1):130. doi: 10.3390/microorganisms8010130.
2
Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota.
Arch Gynecol Obstet. 2018 Jul;298(1):139-145. doi: 10.1007/s00404-018-4771-z. Epub 2018 Apr 10.
3
Role of Lactobacilli and Lactoferrin in the Mucosal Cervicovaginal Defense.
Front Immunol. 2018 Mar 1;9:376. doi: 10.3389/fimmu.2018.00376. eCollection 2018.
4
The role of lactobacilli and probiotics in maintaining vaginal health.
Arch Gynecol Obstet. 2014 Mar;289(3):479-89. doi: 10.1007/s00404-013-3064-9. Epub 2013 Oct 30.
5
Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial.
Benef Microbes. 2019 Feb 8;10(1):19-26. doi: 10.3920/BM2018.0075. Epub 2018 Dec 10.
6
Probiotics in the Prevention and Treatment of Postmenopausal Vaginal Infections: Review Article.
J Menopausal Med. 2017 Dec;23(3):139-145. doi: 10.6118/jmm.2017.23.3.139. Epub 2017 Dec 29.
7
Use of a lactoferrin assay in the differential diagnosis of female genital tract infections and implications for the pathophysiology of bacterial vaginosis.
Sex Transm Dis. 1996 Nov-Dec;23(6):517-21. doi: 10.1097/00007435-199611000-00014.
8
The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review.
J Chemother. 2009 Jun;21(3):243-52. doi: 10.1179/joc.2009.21.3.243.
9
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.
J Obstet Gynaecol Can. 2015 Mar;37(3):266-274. doi: 10.1016/S1701-2163(15)30316-9.
10
Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review.
Clin Ther. 2008 Mar;30(3):453-68. doi: 10.1016/j.clinthera.2008.03.013.
引用本文的文献
1
Efficacy of transvaginal erbium laser treatment for vaginal relaxation and its impact on vaginal microenvironment indicators.
Am J Transl Res. 2025 Apr 15;17(4):2701-2711. doi: 10.62347/BVZV3932. eCollection 2025.
2
Synergistic Inhibition of by Cranberry Proanthocyanidins and Probiotics: Novel Strategies for Vulvovaginal Candidiasis Treatment.
Pathogens. 2025 Mar 24;14(4):308. doi: 10.3390/pathogens14040308.
3
Genome-scale metabolic modeling reveals specific vaginal strains and their metabolites as key inhibitors of .
Microbiol Spectr. 2025 Jun 3;13(6):e0298424. doi: 10.1128/spectrum.02984-24. Epub 2025 Apr 16.
4
Candida albicans: the current status regarding vaginal infections.
Appl Microbiol Biotechnol. 2025 Apr 10;109(1):91. doi: 10.1007/s00253-025-13478-2.
5
Phenylacetic acid, an anti-vaginitis metabolite produced by the vaginal symbiotic bacterium Chryseobacterium gleum.
Sci Rep. 2024 May 28;14(1):12226. doi: 10.1038/s41598-024-62947-7.
6
Instant Detection Using Ultra-Stable Aptamer Conjugated Gold Nanoparticles.
Micromachines (Basel). 2024 Jan 31;15(2):216. doi: 10.3390/mi15020216.
7
Dysbiotic Vaginal Microbiota Induces Preterm Birth Cascade via Pathogenic Molecules in the Vagina.
Metabolites. 2024 Jan 11;14(1):45. doi: 10.3390/metabo14010045.
8
Vaginal Infections during Pregnancy Increase Breast Milk Microbiome Alpha Diversity and Alter Taxonomic Composition.
Prev Nutr Food Sci. 2023 Mar 31;28(1):1-9. doi: 10.3746/pnf.2023.28.1.1.
9
Vaginal and urinary evaluation of lactobacilli quantification by qPCR: Identifying factors that influence urinary detection and the quantity of Lactobacillus.
PLoS One. 2023 Apr 14;18(4):e0283215. doi: 10.1371/journal.pone.0283215. eCollection 2023.
10
High-Throughput Sequencing-Based Analysis of Changes in the Vaginal Microbiome during the Disease Course of Patients with Bacterial Vaginosis: A Case-Control Study.
Biology (Basel). 2022 Dec 10;11(12):1797. doi: 10.3390/biology11121797.
本文引用的文献
1
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure.
Curr Infect Dis Rep. 2019 Nov 9;21(11):44. doi: 10.1007/s11908-019-0700-y.
2
Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs.
BJOG. 2020 Jan;127(2):287-299. doi: 10.1111/1471-0528.15870. Epub 2019 Aug 8.
3
Detection of vaginal lactobacilli as probiotic candidates.
Sci Rep. 2019 Mar 4;9(1):3355. doi: 10.1038/s41598-019-40304-3.
4
Anti-Candida activity of beneficial vaginal lactobacilli in in vitro assays and in a murine experimental model.
FEMS Yeast Res. 2019 Mar 1;19(2). doi: 10.1093/femsyr/foz008.
5
Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis.
BMC Microbiol. 2019 Jan 8;19(1):7. doi: 10.1186/s12866-018-1370-x.
6
Randomised clinical trial in women with Recurrent Vulvovaginal Candidiasis: Efficacy of probiotics and lactoferrin as maintenance treatment.
Mycoses. 2019 Apr;62(4):328-335. doi: 10.1111/myc.12883. Epub 2019 Feb 20.
7
Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial.
Benef Microbes. 2019 Feb 8;10(1):19-26. doi: 10.3920/BM2018.0075. Epub 2018 Dec 10.
8
Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment.
Arch Ital Urol Androl. 2018 Jun 30;90(2):101-103. doi: 10.4081/aiua.2018.2.101.
9
Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota.
Arch Gynecol Obstet. 2018 Jul;298(1):139-145. doi: 10.1007/s00404-018-4771-z. Epub 2018 Apr 10.
10
The Unregulated Probiotic Market.
Clin Gastroenterol Hepatol. 2019 Apr;17(5):809-817. doi: 10.1016/j.cgh.2018.01.018. Epub 2018 Mar 14.
Zotero 插件